title: Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases.
abstract: Psoriasis is a chronic inflammatory skin condition, characterized by T-helper (Th) 1 and Th17 cell activation. Ustekinumab is a fully human immunoglobulin G1κ monoclonal antibody that targets the common p40 subunit that is shared by both interleukin (IL)-12 and IL-23, consequently inhibiting T-cell differentiation along both Th1 and Th17 pathways. This is a report of two patients who developed psoriatic arthritis during ustekinumab treatment for psoriasis. Neither patient had a personal or family history of arthritis.
authors.affiliation: Department of Dermatology, New York University School of Medicine, New York, NY, USA. aieska@yahoo.com
authors.forename: A
authors.initials: A
authors.lastname: de Souza
authors.forename: T
authors.initials: T
authors.lastname: Ali-Shaw
authors.forename: S M
authors.initials: SM
authors.lastname: Reddy
authors.forename: D
authors.initials: D
authors.lastname: Fiorentino
authors.forename: B E
authors.initials: BE
authors.lastname: Strober
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D015535:Arthritis, Psoriatic / Q000139:chemically induced*; D003879:Dermatologic Agents / Q000009:adverse effects*; D006801:Humans; D008297:Male; D011565:Psoriasis / Q000188:drug therapy*; D000069549:Ustekinumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D000069549:Ustekinumab